GTC’s Board of Directors
[This post includes biographical information on each of GTC’s ten directors. With the exception of Christian Béchon, the newest director from LFB, the information below is as given in GTC’s SEC filing for the 2006 annual meeting. Directors are listed below in alphabetical order.]
Robert W. Baldridge, age: 71; term expires 2007; director since 1994:
Mr. Baldridge provided consulting services to GTC from October 1994 to October 2000 and has served as an independent business consultant since June 1988.
Kenneth A. Bauer, MD, age 56; term expires 2009; director since 2004:
Dr. Bauer has been Director of Thrombosis Clinical Research at Beth Israel Deaconess Medical Center since 1997 and has been a Professor of Medicine at Harvard Medical School since 2004, where he has been on the faculty since 1982. Dr. Bauer’s research interests include development of novel laboratory techniques for the detection of prothrombotic states and clinical evaluation of new antithrombotic drugs. Dr. Bauer is the current Chairman of Council for the International Society on Thrombosis and Haemostasis. Dr. Bauer received his Bachelor and Master of Science degrees from the Massachusetts Institute of Technology, and obtained his medical education at Stanford University School of Medicine. He completed subspecialty training in medical oncology and hematology at Dana Farber Cancer Institute and Beth Israel Hospital in Boston.
Christian Béchon , age 46; term expires 2009; director since Dec 2006:
Mr. Béchon is the Chairman and Chief Executive Officer of LFB Biotech, which owns a 19.9% equity stake in GTC. Before joining LFB in 2005, Mr. Béchon held various government posts. He graduated from the Ecole Centrale des Arts et Manufactures engineering school, Institut d'Etudes Politiques de Paris and became a public auditor on leaving the Ecole Nationale d'Administration in 1988.
Francis J. Bullock, PhD, age 69; term expires 2008; director since 1994:
Dr. Bullock is an independent consultant. Prior to that he was a senior consultant with Arthur D. Little, Inc. and with Strategic Decisions Group from September 1993 to March 2003, and a Senior Vice President, Research Operations at Schering-Plough Research Institute from 1981 until August 1993. Dr. Bullock is also a director of Array Biopharma, Inc., a chemical drug discovery services company.
Geoffrey F. Cox, PhD, age: 62; term expires 2008; director since 2001:
Dr. Cox has served as Chairman of the Board, Chief Executive Officer and President of GTC since July 2001, after being elected a director in May 2001. From 1997 to June 2001, Dr. Cox was Chairman and Chief Executive Officer of Aronex Pharmaceuticals, Inc., a biotechnology company. In 1984, Dr. Cox joined Genzyme Corporation in the U.K. and, in 1988, became Senior Vice President of Operations in the United States. Subsequently, Dr. Cox was promoted to Executive Vice President of Operations of Genzyme, and was also responsible for the pharmaceutical, diagnostic and genetics business units until 1997. Prior to joining Genzyme, Dr. Cox was General Manager of U.K. manufacturing operations for Gist-Brocades. Dr. Cox also serves as a director of Nabi Biopharmaceuticals and is a member of the Emerging Companies Section Governing Body and the Board of the Biotechnology Industry Organization.
James A. Geraghty, age 51, term expires 2007; director since 1993:
Mr. Geraghty held the role of Chairman of the Board of Directors of GTC from January 1998 to July 2001. Mr. Geraghty has served as Senior Vice President of Genzyme Corporation since January 2001 and, prior to that served as President of Genzyme Europe from July 1998 to December 2000. Mr. Geraghty was the President and Chief Executive Officer of GTC from its incorporation in February 1993 until July 1998.
Michael J. Landine, age 52; term expires 2007; director since 2004:
Mr. Landine currently guides all areas of corporate development at Alkermes, having been appointed Vice President, Corporate Development in 1999. Mr. Landine joined Alkermes in 1988 as Vice President and Chief Financial Officer, a position he held for ten years. Previously, he was the Chief Financial Officer of The Walker Magnetics Group, Inc., an international manufacturer of industrial equipment. Mr. Landine serves on the Board of Directors of a private life sciences company, Expressive Constructs, Inc., and on the Board of Kopin Corporation, Inc., a manufacturer of high definition imaging products. He is also an advisor to the Board of Directors of The Walker Magnetics Group, Inc. Mr. Landine received a B.S. in Accounting from Bentley College and is a Certified Public Accountant.
Pamela W. McNamara, age 48; term expires 2009; director since 2002:
Since October 2003, Ms. McNamara has been Chief Executive Officer of CRF, Inc., a clinical trial data management and mobile technology company. Prior to that, Ms. McNamara was a private consultant. Ms. McNamara was appointed Chief Executive Officer of Arthur D. Little, Inc., a global management and technology firm, from 2001 to February 2002, to develop plans to restructure, reorganize or divest the firm’s viable business units. In February 2002, Arthur D. Little filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code to provide a framework under which these plans could be executed. Ms. McNamara served as Managing Director of Arthur D. Little from 1997 to 2001, and had been a partner since 1992, focusing on the pharmaceutical and biotechnology industries.
Marvin L. Miller, age 69; term expires 2009; director since 2002:
Mr. Miller has been Executive Chairman of Onconova Therapeutics, Inc. since 2002. Mr. Miller retired in 2002 as President and Chief Executive Officer of Nextran, a subsidiary of Baxter Healthcare Corporation. Before joining Nextran in 1995, Mr. Miller served as Vice President of Biotechnology Licensing for the Pharmaceutical and Agricultural Divisions of American Cyanamid Company since 1987. Previously, Mr. Miller was a Vice President of Johnson & Johnson International from 1983 to 1986. Mr. Miller is a director of Unigene Laboratories, Inc. and the National Center for Genome Resources.
Alan W. Tuck, age 57; term expires 2008; director since 1993:
Mr. Tuck is a partner of The Bridgespan Group, a nonprofit consulting organization where he has worked since April 2001. Mr. Tuck retired in June 2000 as Chief Strategic Officer of Organogenesis Inc., a tissue engineering firm where he had been since July 1997. From February 1992 through May 1996, Mr. Tuck was President and Chief Executive Officer of T Cell Sciences, Inc. Mr. Tuck is also a director of Apogee Technology, Inc., a developer of nanotechnology products.
<<
